GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » Market Cap
中文

Kala Bio (Kala Bio) Market Cap : $18.03 Mil (As of Apr. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kala Bio's share price for the quarter that ended in Dec. 2023 was $7. Kala Bio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 2.76 Mil. Therefore, Kala Bio's market cap for the quarter that ended in Dec. 2023 was $19.32 Mil.

Kala Bio's quarterly market cap declined from Jun. 2023 ($37.04 Mil) to Sep. 2023 ($23.97 Mil) and declined from Sep. 2023 ($23.97 Mil) to Dec. 2023 ($19.32 Mil).

Kala Bio's annual market cap declined from Dec. 2021 ($79.26 Mil) to Dec. 2022 ($65.12 Mil) and declined from Dec. 2022 ($65.12 Mil) to Dec. 2023 ($19.32 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kala Bio's Enterprise Value for Today is $3.92 Mil.


Kala Bio Market Cap Historical Data

The historical data trend for Kala Bio's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only 133.16 399.45 79.26 65.12 19.32

Kala Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.12 34.75 37.04 23.97 19.32

Competitive Comparison

For the Biotechnology subindustry, Kala Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kala Bio Market Cap Distribution

For the Biotechnology industry and Healthcare sector, Kala Bio's Market Cap distribution charts can be found below:

* The bar in red indicates where Kala Bio's Market Cap falls into.



Kala Bio Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Kala Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7*2.75937
=$19.32

Kala Bio's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$7*2.75937
=$19.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kala Bio  (NAS:KALA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Kala Bio Market Cap Related Terms

Thank you for viewing the detailed overview of Kala Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Kala Bio (Kala Bio) Business Description

Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Executives
Todd Bazemore officer: Chief Operating Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell officer: Chief Medical Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg officer: See Remarks 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi officer: CHIEF BUSINESS OFFICER C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki director, officer: Chief Executive Officer 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth officer: Chief Financial Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid director C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen officer: Chief Scientific Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg director 100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116